ArriVent BioPharma is a clinical-stage biopharmaceutical company that identifies, develops, and commercializes differentiated medicines for patients with difficult-to-treat cancers. Founded in 2021, the company is built around a global drug-development model that identifies promising therapies originating in markets including China, Europe, South Korea, and Japan and advances them for patients worldwide.

ArriVent’s lead program is firmonertinib, an oral EGFR inhibitor being developed globally for forms of non-small cell lung cancer driven by uncommon EGFR mutations. The company is also building a pipeline of next-generation antibody-drug conjugates, including programs targeting gastrointestinal, ovarian, endometrial, and other solid tumors. Through partnerships with biotechnology companies and its own drug-development capabilities, ArriVent works to move differentiated oncology assets through clinical development, regulatory approval, and commercialization across global markets.